General Overview

We added 16 PCTs and 26 U.S. patent applications focused on psychedelics to our tracker in the month of April 2024. New entries came from the likes of Psilera, Aya Biosciences, Algernon, ASRI, Terran, GH Research, and more. 

(Subscribe or sign-in, below, to explore the interactive tables.)

***

A CaaMTech & ASRI Collaboration

In early April, a shared PCT (WO2024073356) from psychedelic drug developers the Alexander Shulgin Research Institute (ASRI) and CaaMTech was published. The PCT appears to be the first IP product to emerge from a collaboration between the two parties that was announced nearly two years ago.

Since its inception, CaaMTech has worked to synthesise and characterise solid forms of dozens of psychedelics. The company’s drug discovery work, largely focused on tryptamines, has supported the creation of a patent portfolio consisting of around three dozen PCTs and many more national stage entries. In addition to its intellectual property pursuits, CaaMTech’s fundamental science efforts have translated into more than two dozen publications since 2019.

At the same time, since its founding in 2021, ASRI has worked to develop and advance its own portfolio of novel psychedelics. A number of the company’s PCT have published since early 2023 (WO2024006226, WO2023034645, WO2023028091 & WO2023028092), and more recently the company’s first patent U.S. application (US 18/549,374) was allowed, which received fast track examination under the Patent Prosecution Highway...